Janux Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 11.76 million compared to USD 16.07 million a year ago. Basic loss per share from continuing operations was USD 0.25 compared to USD 0.39 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
53.5 USD | +6.13% | +17.92% | +398.60% |
May. 30 | Scotiabank Starts Janux Therapeutics With Sector Perform Rating | MT |
May. 30 | Certain Pre Funded Warrants of Janux Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024. | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+398.60% | 2.77B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- JANX Stock
- News Janux Therapeutics, Inc.
- Janux Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023